Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
about
Only one isoform of Drosophila melanogaster CTP synthase forms the cytoophidiumPrevention of poxvirus infection by tetrapyrrolesCrystal structure of poxvirus thymidylate kinase: An unexpected dimerization has implications for antiviral therapyStructural determinants for the inhibitory ligands of orotidine-5′-monophosphate decarboxylaseStructural requirements for the activation of Escherichia coli CTP synthase by the allosteric effector GTP are stringent, but requirements for inhibition are laxEfficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine for treatment of vaccinia virus (orthopoxvirus) infections in miceEfficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in miceA cutting-edge view on the current state of antiviral drug development.Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovirEfficacy of cidofovir in a murine model of disseminated progressive vaccinia.Use of the Aerosol Rabbitpox Virus Model for Evaluation of Anti-Poxvirus Agents.Ligand-induced and nonfusogenic dissolution of a viral membrane.Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections.Toward orthopoxvirus countermeasures: a novel heteromorphic nucleoside of unusual structure.Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication.Smallpox and live-virus vaccination in transplant recipients.Carbocyclic pyrimidine nucleosides as inhibitors of S-adenosylhomocysteine hydrolase.Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.Aurintricarboxylic acid inhibits the early stage of vaccinia virus replication by targeting both cellular and viral factors.Vaccinia as a vector for gene delivery.Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus.Antivirals and antiviral strategies.Orthopoxvirus targets for the development of antiviral therapies.A survey of antiviral drugs for bioweapons.Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in miceFrom actually toxic to highly specific--novel drugs against poxviruses.Inosine monophosphate dehydrogenase as a probe in antiviral drug discovery.SOCS-1 mimetics protect mice against lethal poxvirus infection: identification of a novel endogenous antiviral system.Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.Orthopoxvirus targets for the development of new antiviral agents.Camelpox: epidemiology, diagnosis and control measures.Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses.The design and development of drugs acting against the smallpox virus.Design of inhibitors of ODCase.Antiviral Activity of 4'-thioIDU and Thymidine Analogs against OrthopoxvirusesHistorical perspectives in the development of antiviral agents against poxvirusesIdentification of a pyridopyrimidinone inhibitor of orthopoxviruses from a diversity-oriented synthesis libraryEffect of 5-iodo-2'-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice.Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures.Yeast-based genetic system for functional analysis of poxvirus mRNA cap methyltransferase.
P2860
Q21563363-E773C163-D1C9-4525-9356-D834480E73BAQ24806638-A7DDC869-7F3E-4101-A08D-98E482434662Q27652695-B3AD6E28-5818-430F-BE62-BF78FA9BE6CFQ27661430-0C4EC31F-9146-4F59-9AC9-377276395002Q28257328-ED2D5DBD-4326-4DE0-A4FA-7588FBFA7501Q28345238-015F89E2-2C8D-4F74-8766-74EB8958151DQ28396760-E4669A8B-429F-4F98-8055-2940D5CFFE65Q34036018-33BFA7D2-B5AD-4140-BCDB-8E51ECC03551Q34106327-006C5E05-03B0-4724-A72E-565CA4C8854DQ34140816-D8B280A2-42F7-4CBD-AF34-7445FDBD42E7Q34196187-10B5156F-A2E4-4777-9C5D-B78346C2A809Q34507126-16BEA45F-ADA5-419B-B7CA-934A70C65D0DQ34510424-75284A3F-A9BE-4D7C-8D19-3EE7F3179B01Q34984243-63C96E77-904B-42DA-8CC5-17624A5A0912Q35103702-F139B523-B6E9-4D8E-AE7F-AC03A2137B59Q35157553-EF3A0CA9-4CAB-44F4-989B-F120DF01B021Q35225512-5BFA8BBB-70ED-4B25-952D-519D5ED4F995Q35558801-CA0C3B2F-B2D4-4AF7-9A4C-5A31BDB294E7Q35784850-C92F94DA-9E28-45EF-A87B-BF753AC45DFFQ35790868-DFCB6071-C16D-477F-A061-06E660F81F21Q35842621-736A3E90-92D8-4819-BFEA-698F457B1F39Q35889586-22F69D40-29DA-49B1-B455-C6E9B65F3950Q36074391-6BE86633-97C6-40A8-AED1-360665A8D152Q36295162-16931DD8-D3DC-4DA0-95F9-8B59AADD80D1Q36295406-923AF108-CD7D-4981-9FBD-6D03C6EBAE3BQ36708435-5DCAF527-993F-47B7-BD2C-E533477FF484Q37018993-3EE94C81-F5B0-482D-9801-5F3387FBCABFQ37051663-1D784EBF-80E6-452A-95FC-9CC5B2B69AE0Q37072113-2B864388-9FEB-490D-A279-5E4435CE8BC9Q37173398-4E234F61-B30F-48EE-911A-F147AB92C66DQ37800922-F97C9413-761D-432A-B16B-3C209DA1EF99Q37828538-FDDA8E0E-A269-4F3C-887A-6407CBAD54CEQ38089868-58975CA7-A492-4558-A3EB-05E7B5BDB756Q38182137-EC76A158-8793-4C2A-B3BB-920BB7C4496AQ38615818-75FFDDCF-4576-4F33-9137-561472078446Q38617932-1D74ED34-1679-40F8-94BF-25BECA8175EFQ39420959-25560DC9-96EE-4CC9-B084-499B9A9F4E6EQ39652802-4B91BFD4-FF16-4B18-BF4A-CA703F6C03B3Q39657990-E5E709D8-E7B1-4C96-905E-A65CDCA1EC42Q39787657-98579B71-0AC3-46F6-943F-351D558D22E7
P2860
Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
@ast
Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
@en
Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
@nl
type
label
Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
@ast
Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
@en
Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
@nl
prefLabel
Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
@ast
Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
@en
Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
@nl
P2860
P1476
Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
@en
P2093
E De Clercq
P2860
P304
P356
10.1128/CMR.14.2.382-397.2001
P407
P577
2001-04-01T00:00:00Z